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Viruses modulate biochemical cellular pathways to permit infec-
tion. A recently described mechanism mediates selective protein
interactions between acidic domain readers and unacetylated,
lysine-rich regions, opposite of bromodomain function. Kaposi´s
sarcoma (KS)-associated herpesvirus (KSHV) is tightly linked with
KS, primary effusion lymphoma, and multicentric Castleman’s dis-
ease. KSHV latently infects cells, and its genome persists as a mul-
ticopy, extrachromosomal episome. During latency, KSHV expresses
a small subset of genes, including the latency-associated nuclear
antigen (LANA), which mediates viral episome persistence. Here
we show that LANA contains two tandem, partially overlapping,
acidic domain sequences homologous to the SET oncoprotein acidic
domain reader. This domain selectively interacts with unacetylated
p53, as evidenced by reduced LANA interaction after overexpression
of CBP, which acetylates p53, or with an acetylation mimicking
carboxyl-terminal domain p53 mutant. Conversely, the interaction
of LANA with an acetylation-deficient p53 mutant is enhanced. Sig-
nificantly, KSHV LANA mutants lacking the acidic domain reader
sequence are deficient for establishment of latency and persistent
infection. This deficiency was confirmed under physiological condi-
tions, on infection of mice with a murine gammaherpesvirus 68 chi-
mera expressing LANA, where the virus was highly deficient in
establishing latent infection in germinal center B cells. Therefore,
LANA’s acidic domain reader is critical for viral latency. These results
implicate an acetylation-dependent mechanism mediating KSHV
persistence and expand the role of acidic domain readers.
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Lysine acetylation is emerging as an important posttransla-tional modification that regulates the function of proteins as
well as histones. Acetylation is determined through a dynamic
interplay between acetyltransferases and deacetylases. Bromo-
domains and acidic domains containing proteins typified by the
SET oncoprotein are readers of acetylated and unacetylated li-
gands, respectively. Perhaps the best-characterized acetylation-
dependent regulation of a nonhistone protein is of tumor-
suppressor protein p53 (1). Phosphorylation at N-terminal p53
allows recruitment of the closely related cotranscription factors
CBP/p300, which can acetylate lysine residues in the p53 carboxyl-
terminal domain. Complexes of p53 and CBP/p300 recognize
specific promoter sequences to initiate the transcription of p53-
targeted genes. Bromodomains, such as those present in CBP/
p300, interact with acetylated lysines by structurally forming a
hydrophobic pocket (2). Conversely, acidic domain readers bind to
positively charged unacetylated clusters of lysines. p53-SET com-
plexes bind to p53-targeted promoters, blocking transcription (3).
Therefore, p53-driven transcription is regulated through an in-
terplay between bromodomain acetylation-dependent activation
and acidic domain unacetylated-dependent repression.
Kaposi’s sarcoma (KS)-associated herpesvirus (KSHV) is etio-
logically linked to KS, primary effusion lymphoma, and multicentric
Castleman’s disease (4–7). During latent infection of B cells, KSHV
expresses a limited number of proteins, including the latency-
associated nuclear antigen (LANA) (8). LANA is a 1,162 amino
acid protein with an N-terminal proline-rich region, a C-terminal
region containing a DNA-binding domain, and extensive central
repetitive sequence, including an aspartic and glutamic acid rich
region (Fig. 1).
A critical function of LANA is mediation of viral episome
persistence by mediating the replication and tethering of viral
genomes to host mitotic chromosomes to allow segregation to
progeny nuclei during latent infection of proliferating cells
(15–18). Some molecular aspects of this function are well char-
acterized. LANA amino acids 5 to 13 encode a chromosome-
binding motif that binds histones H2A/H2B (11). The C-terminal
LANA region self-associates to bind chromatin and recognizes
specific DNA sequences within the terminal repeat (TR) region
of KSHV episomes. In addition to episomal persistence, other
functions have been ascribed to LANA, including transcriptional
activity and growth effects on the cell. An example is inhibition
of host nuclear factor-kappa B (NF-κB) transcriptional activity
through polyubiquitination and subsequent proteasomal-dependent
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nuclear degradation of the NF-κB family member p65/RelA
(19, 20). This mechanism involves the assembly of an ElonginC/
Cullin5/SOCS (suppressors of cytokine signaling)-like complex,
mediated by an unconventional viral SOCS-box motif present
in LANA. The related murine gammaherpesvirus 68 (MHV-68)
LANA has an EC5S that also targets cellular control of Myc
turnover by antagonizing SCF(Fbw7)-mediated proteasomal
degradation of Myc, mimicking SCF(β-TrCP) (21). However,
much remains to be defined regarding how LANA interacts with
cellular proteins to exert its functions.
Here we show that LANA contains two tandem, partially
overlapping acidic domain sequences, homologous to the SET
acidic domain reader sequence. This domain mimics SET’s
preferential binding of the unacetylated p53 C-terminal domain.
Viruses lacking the acidic domain reader were deficient in
establishing latent infection and virus persistence, including in
germinal center B cells. Therefore, LANA’s acidic domain
reader is a key element mediating virus persistence and likely
KSHV-associated oncogenesis.
Materials and Methods
Cell Lines. 293T cells were maintained in DMEM (Corning) supplemented with
10% bovine growth serum (GE Healthcare) and 15 ug/mL gentamicin
(Gemini). Baby hamster kidney (BHK-21) fibroblasts were maintained in
GMEM (Gibco) supplemented with 10% fetal bovine serum (Gibco), 50 U/mL
penicillin, 50 ug/mL streptomycin (Gibco), 2 mM L-glutamine (Gibco), and
10% tryptose phosphate broth (TPB) (Sigma-Aldrich). NIH 3T3-CRE cells were
maintained in DMEM (Gibco) supplemented as for BHK-21 cells without
TPB (22).
Plasmids and BACs. pT7LANA, pT7LANAΔ262–320, pT7LANAΔ288–320,
pT7LANAΔ332–929, and pT7LANAΔ465–929 have been described previously
(13, 14). HA-CBP (23) was a gift from Wei Gu, Columbia University.
BAC16(21)and pEPCMV-in (24) were gifts from Jae Jung, University of
Southern California. pcDNA3 flag p53 was generated by Thomas Roberts
and obtained from Addgene (25). To generate pEGFP-NLS-LANA 275–435,
GFP LANA 274–777 (26) was digested with AclI (located at LANA codon 435)
and BamHI (located immediately downstream of the LANA ORF in the pol-
ylinker.) Oligonucleotides 5′-CGTGATAAATCAGCTGATAACCCTGTTCGAGA
GCTACGTCGTAGCG-3′ and 5′-GATCCGCTACGACGTAGCTCTCGAACAGGGTT
ATCAGCTGATTTATCA-3′ were annealed to generate a linker with a 5′
compatible AclI overhang (indicated in italics) and a 3′ compatible BamHI
overhang (indicated in bold). Stop codons immediately following the AclI
overhang are underscored. The linker was ligated with AclI/BamHI-digested
GFP LANA 274–777 to generate pEGFP-NLS-LANA 275–435.
BACΔLANA was generated by removing LANA from BAC16 as follows.





in bold, BAC16 sequences lowercase, kanamycin cassette sequence under-
scored). The PCR fragment was then recombined into BAC16 in the LANA gene
as described previously (24) (SI Appendix, Fig. S1, Left). In brief, PCR- amplified
DNA was electroporated using a BTX Escherichia coli TransPorator (1.8 kV, 0.1-
cm cuvette) into GS1783 E. coli cells (a gift from Jae Jung) containing BAC16.
The bacteria transiently expressed the proteins gam, bet, and exo, which are
temperature-inducible in GS1783 cells. These proteins are necessary for the
homologous recombination of linear DNA fragments. Clones were selected for
kanamycin resistance, and the deletion of LANA was verified by PCR and by
sequencing of the PCR products. NheI restriction enzyme digestion confirmed
the absence of the LANA containing BAC DNA fragment in BACΔLANA (SI
Appendix, Fig. S2 A and B).
The kanamycin resistance was subsequently removed in a “scarless”
fashion as described previously (24). In brief, the arabinose-inducible gene
encoding the I-SceI enzyme was expressed following 1% arabinose treat-
ment, resulting in linearization of the BAC by cleavage in the kanamycin
gene. Following linearization, the BAC was recircularized by transient in-
duction of gam, bet, and exo to enable recombination between duplicated
sequences flanking the kanamycin cassette, resulting in kanamycin loss from
the BAC (SI Appendix, Fig. S1, Left). Kanamycin-sensitive clones were then
identified via replica plating. Deletion of LANA was again verified by PCR,
followed by sequencing of the PCR fragments, and the number of TRs was
assessed by NheI digestion followed by pulsed-field gel electrophoresis
(PFGE) (CHEF-DR II; Bio-Rad).
BAC LANA-R, BAC LANA-R Δ262–320, BAC LANA-R Δ288–320, BAC LANA-
R Δ332–929, BAC LANA-R Δ465–929, and BAC LANA-R Δ331–495 were each
obtained following recombination of transfer plasmid restriction fragments
for each respective clone into BACΔLANA. To generate the WT LANA
transfer plasmid, the kanamycin resistance gene from pEPCMV-in was am-
plified using primers 5′-ATA CGT TGA TAT CTA GGG ATA ACA GGG TAA TCG
ATT TAT TC-3′ (EcoRV site in italics, kanamycin cassette sequence under-
scored) and 5′-GAT TAG GTC TAG Acg gtg gct tct agg gag gaa aaa ggg gga
gag gtg tgg ctT TTA TGT CAT TTC CTG TGG AGA GTC CCC AGG ACC TTG GTT
TGC TAG CCA GTG TTA CAA CCA ATT AAC C-3′ (XbaI site in italics, LANA
sequence in bold, BAC16 sequence lowercase, kanamycin cassette sequence
underscored). The resulting PCR product was cloned into pT7LANA following
digestion with EcoRV and XbaI to generate the transfer plasmid containing
the kanamycin expression cassette immediately downstream of LANA (SI
Appendix, Fig. S1, Right).
To generate transfer plasmids for LANA mutants, XhoI/BamHI restriction
fragments from pT7LANAΔ262–320, pT7LANAΔ288–320, pT7LANAΔ332–929,
pT7LANAΔ465–929, or pT7LANAΔ331–495 were each introduced into the
pT7LANA transfer plasmid following XhoI/BamHI digestion. (XhoI cuts just
before the LANA ORF in pT7LANA, and BamH1 cuts at LANA codon 273.)
Before recombination, all transfer plasmids were amplified in Dam-negative
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Fig. 1. Schematic representation of KSHV LANA and LANA mutants. The amino terminal bipartite nuclear localization signal (NLS) at residues 24 to 30 and 41
to 47 (9, 10) is indicated by the two vertical black bands. LANA regions identified include proline-rich (P), aspartate- and glutamate-rich (DE), glutamine-rich
(Q), glutamate- and glutamine-rich (EQE), and putative leucine zipper (LZ). The DE, Q, LZ, and EQE regions each contain imperfect repeat elements. Residues 5
to 13 mediate chromosome association through interaction with histones H2A/H2B (11, 12). Residues 996 to 1,139 bind TR DNA, mediate self-association, and
associate with mitotic chromosomes. The capabilities for DNA replication, episome segregation, LANA mediated episome persistence, and KSHV persistence in
cells are summarized at the right. *Data from refs. 13 and 14. NT, not tested.




































releases a fragment containing LANA and the downstream kanamycin cas-
sette. The DNA fragments were recombined in BACΔLANA in a scarless fashion
as described above.
The number of TR copies within each BAC clone was assessed by NheI
digestion, followed by PFGE using 1% PFGE-grade agarose, at 5.5 V/cm for 16
h, an initial switch time of 1 s, and a final switch time of 5 s at 14 °C. NheI
does not cut within the tandem TRs. KSHV contains approximately 40 TR
copies of the 0.8-kb GC-rich TR element (27, 28). We observed that during
BAC construction, the number of KSHV TRs was frequently reduced, pre-
sumably due to recombination events. Since LANA acts on the TRs to me-
diate episome persistence, and since TR copy number can affect LANA
episome maintenance efficiency (29), we screened BAC recombinants with
PFGE after NheI digestion to identify those with a full complement of TRs (SI
Appendix, Fig. S2 C and D).
The recombinant BACs were confirmed for the ability to express GFP
(BAC16 encodes a GFP expression cassette) following transfection into
293T cells (SI Appendix, Fig. S3). The recombinant BACs were also confirmed
to be competent for the production of infectious KSHV following the in-
duction of lytic replication, as described below (SI Appendix, Fig. S4).
pcDNA3 flag p53 encodes a 3× Flag epitope tag at the N terminus of p53.
p53 containing substitution mutations was generated using reverse-
orientation primers containing the mutated sequence to amplify the en-
tire 3× Flag-p53 plasmid. The PCR amplification product was then incubated
for 1 h with DpnI to digest template DNA and circularized using T4 ligase
before transformation into E. coli bacteria. In brief, primer pairs P53-37023-
RR: GGAGCGCAGGTGGCTGGAGTGAGCCCT and P53-37023-RF: CGCCGCGGT
CAGTCTACCTCCCGCCA (arginine codons in bold and italics) were used to
amplify 3× Flag-p53 plasmid to mutate amino acids 370K, 372K, and 373K to
arginines. The resulting mutant 3× Flag-p53 plasmid was then amplified by
P53-38126-RR: GAGGCGGCGATGGCGGGAGGTAGACTGAC and P53-38126-
RF: ATGTTCCGCACAGAAGGGCCTGACTCAG to mutate amino acids 381K,
382K, and 386K to arginines. Similarly, primers P53-37023-QR: GGACTGCAG
GTGGCTGGAGTGAGCCCT and P53-37023-QF: CAGCAGGGTCAGTCTACCTCC
CGCCA (glutamine codons in bold and italics) were used to amplify 3× Flag-
P53 plasmid to mutate amino acids 370K, 372K, and 373K to glutamines. The
resulting mutant 3× Flag-P53 plasmid was then amplified using P53-38126-
QR: GAGCTGCTGATGGCGGGAGGTAGACTGAC and P53-38126-QF: ATG
TTCCAGACAGAAGGGCCTGACTCAG to mutate amino acids 381K, 382K, and
386K to glutamines. All plasmids containing substitution mutations were
sequence-confirmed.
pSP72 PCR 1_5 contains the kLANAORF and its 5′UTR (U75698; nts 123,808
to 127,886), flanked by MHV-68 DNA sequences (U97553; 104,710 to
105,092, upper flank; 102,728 to 103,934, lower flank) (30). pBamHI-G con-
tains the MHV-68 BamHI G fragment (nts 101,653 to 106,902), which includes
the mLANA ORF (nts 104,868 to 103,927) cloned into the BamHI site of the
pST76K-SR (31) shuttle vector. DNA fragments comprising kLANA internal
deletions were each subcloned into pSP72 PCR 1_5 from pT7 kLANAΔ332–929
and pT7 kLANAΔ465–929 (using BamHI/StuI). To create kLANA Δ331–495, the
region between a PstI site in the 5′ UTR of kLANA (genomic nt 127,434) and
codon 330 of kLANA was amplified with primers IMMAF3 (5′-GTACTGCAGCCT
GCTACTGTG-3′; 5′ UTR PstI site in bold) and IMM AF2 (5′-AAACTGCAGATCCTT
ATTGTCATTGTCATC-3′; kLANA codon 330 underscored, introduced PstI site in
bold) from pSP72_PCR1_4. pSP72_PCR1_4 is pSP72 PCR 1_5 without the lower
MHV-68 flank (30). The PCR product was cloned into pSP72-PCR1_4 using PstI,
replacing wild type by Δ331–495 kLANA sequences. The lower flank of MHV-
68 was subcloned from pSP72-PCR1_5 into pSP72-PCR1_4 kLANA Δ331–495
using XhoI/HindIII. BglII-DNA fragments comprising mutant kLANA ORFs, the
kLANA ORF 5′ UTR, and MHV-68 flanks were excised from each mutant pSP72-
PCR1_5 and subcloned into the into BglII sites (MHV-68 genomic nts 102,728
and 105,087) of pBamHI-G. Mutant pBamHI-G shuttle vectors were recom-
bined with wild-type MHV-68 BAC (pHA3) (31) or a yellow fluorescent protein
(YFP) MHV-68 BAC (32) in E. coli. BAC recombinant clones were identified by
colony PCR specific for kLANA and by analysis of EcoRI, BamHI, and HindIII
restriction profiles of BAC DNA prepared from PCR-positive clones. Indepen-
dent clones were generated for each virus.
Antibodies. KSHV LANA was detected using anti-LANA rat mAb (LN53) (13-
210-100; ABI Sciences) and anti-LANA Ab (13). MHV68 LANA was detected
with mAb 6A3 (30). Flag-p53 was detected using either anti-Flag M2
(Sigma-Aldrich) or p53 Ab (PA5-27822; Thermo Fisher Scientific). HA-CBP was
detected using anti-CBP (A300-363A; Bethyl). GFP was detected with either
mouse anti- GFP Ab (14-6674-82; Thermo Fisher Scientific) or rabbit anti-GFP
(ab183734; Abcam). Actin was detected with an anti-actin rabbit polyclonal
Ab (A2066; Sigma-Aldrich). Anti-CD19 APC-H7 (1D3) (557655; BD Biosciences),
anti-GL-7 eF660 (GL7) (50-5902-82; eBioScience), and anti-CD95 PE (Jo2) (554258;
BD Pharmingen) were used for FACS.
BAC Transfection, KSHV Production, and Infection. KSHV BAC DNAwas purified
from GS1783 E. coli cells using Midiprep kits (Macherey-Nagel). BACΔLANA,
BACLANA-R, or BACLANA-R mutants were transfected into 293T cells with
Lipofectamine 3000 (Thermo Fisher Scientific) following the manufacturer’s
protocol. Clonal selection was obtained using 0.2 mg/mL hygromycin (EMD
Millipore). To assess the ability of the recombinant virus to produce virions,
lytic reactivation was induced shortly after establishment of 293T stable cell
lines containing BACΔLANA, BACLANA-R, or BACLANA-R LANA. Reac-
tivation was induced overnight using TPA (20 ng/mL; Sigma-Aldrich) and
sodium butyrate (32 mM; Alfa Aesar). At 5 d after reactivation, supernatant
was harvested, filtered through a 0.45-μm filter (Celltreat), and used to in-
fect 293T cells by spinoculation at 1,500 rpm for 1 h at room temperature.
Cells were imaged using a Zeiss Axiovert microscope to assess for GFP ex-
pression from the recombinant BAC16.
LANA Expression Level. 293T cells were transfected with BACΔLANA,
BACLANA-R, or BACLANA-R mutants and then harvested after 24 h. DNA
was harvested from one-half of the cells using the Hirt extraction method
(33). RNA was harvested from the other one-half of the cells by TRIzol (Life
Technologies), following the manufacturer’s protocol. RNAs were treated by
RQ1 DNase (Promega) and then reverse-transcribed using the iScript Reverse
Transcription Kit (Bio-Rad). Quantitative PCR (qPCR) was performed on DNA
or cDNA using PowerUp CyberGreen Master Mix (Thermo Fisher Scientific)
and LANA ORF73 primers 5′-GATGATTGTCCTGCGAAAGC-3′ and 5′- TTGGAT
CTCGTCTTCCATCC-3′. The level of LANA cDNA was then divided by the level
of LANA DNA (present in the virus genome) to determine LANA expression
relative to the amount of virus DNA present for LANA or each LANA mutant.
LANA expression levels from infected BHK-21 cells were quantified by
extracting cDNA (5 PFU/cell for 8 h) as described previously (34). Real-time
qPCR was performed with the DyNAmo SYBR FlashGreen qPCR kit (Thermo
Fisher Scientific), using primers specific for DNA encoding the C-terminal
region of kLANA, (kLANA RT2-F: 5′-TGGTTGTTGGTATCTTGG-3′ and kLANA
RT2-R: 5′-CCTGGAGTTCGTATGAGG-3′), and previously described primers for
MHV68 M3 and for glyceraldehyde-3-phosphate dehydrogenase (34). ΔΔCT
values (where CT is the threshold cycle) were calculated.
Colony Outgrowth Assays. BACΔLANA, BACLANA-R, or BACLANA-R mutants
were transfected in 293T cells using Lipofectamine 3000. At 48 h after
transfection, cells were assessed by flow cytometry for GFP expression
(constitutively expressed from recombinant BAC16) and also counted man-
ually. Total cell suspensions containing 1,000 GFP-expressing cells were
plated in 15-cm dishes placed under 0.2 mg/mL hygromycin selection, for
which resistance is encoded by BAC16. After 2.5 wk of selection, clones were
stained with crystal violet and counted manually.
Western Blot and Immunoprecipitation Assays.Uninfected and infected (3 PFU/
cell, 6 h) cell monolayers were washed three times with ice-cold PBS and
scraped into lysis buffer (10 mM Tris·HCl pH 7.4, 150 mM NaCl, 1 mM NaF,
1 mM orthovanadate, 1% Triton X-100, and cOmplete Protease Inhibitor
[Roche]). After a 20-min incubation on ice, samples were centrifuged at
18,000 × g for 10 min at 4 °C, and cleared lysates were analyzed by
Western blot.
For immunoprecipitation experiments, 293T cells were transfected with
the indicated plasmids using Lipofectamine 3000. Given our finding that CBP
increases LANA expression and p53 decreases LANA or CBP expression, the
amounts of transfected plasmids were adjusted to obtain similar LANA and
p53 levels. Then 48 h later, cells were scraped into 1× PBS, and pellets were
lysed in TNE buffer (100 mM Tris·HCl pH 8, 100 mM NaCl, 1 mM EDTA, and
protease inhibitor [Thermo Fisher Scientific]) for 30 min on ice, followed by
centrifugation for 10 min at 10,000 rpm. Then 20 μL of Dynabeads Protein G
(Invitrogen) was incubated with 4 μg of M2-Flag Ab (Sigma-Aldrich) in TNE
buffer for 2 h at 4 °C, followed by two washings with TNE buffer. The Ab-
bound Dynabeads were incubated with cell lysate supernatant overnight at
4 °C with 2,000 U/mL micrococcal nuclease and 10 mM CaCl2 included in the
incubation. Beads were washed five times in IPP50 buffer (10 mM Tris·HCl pH
8, 150 mM NaCl, and 1% Triton X-100) with protease inhibitor and then
boiled for 10 min.
For immunoprecipitations with p53 mutants, 5 μg of plasmid encoding
GFP-LANA or GFP-LANA 275–435 was cotransfected with 5 μg of plasmid
encoding 3FLAG-p53, 3FLAG-p53 KR, or 3Flag-p53 KQ into cells in 10-cm
dishes containing 293T cells at 70% confluence using lipofectamine 3000
regent (Thermo Fisher Scientific). After incubation at 37 °C for 48 h, cells












































were lysed in lysis buffer (20 mM Tris pH 7.9, 137 mM NaCl, 1% Triton X-100,
10 mM CaCl2, 2 mM EDTA, 10% glycerol, and 2000 U/mL micrococcal nu-
clease) and subjected to centrifugation to obtain cell lysate supernatant.
Dynabeads Protein G (Invitrogen) were incubated with mouse anti-Flag
monoclonal Ab (Sigma-Aldrich; 1804) in lysis buffer for 30 min at 37 °C
and then washed three times with lysis buffer. The Flag Ab-bound Dyna-
beads were then incubated with cell lysate supernatant overnight at 4 °C.
Input (5%) and immunoprecipitates were analyzed by Western blot analysis
with rabbit monoclonal anti-GFP (Abcam; 183734) to detect GFP-LANA or
GFP-LANA 275–435 or with mouse anti-Flag (Sigma-Aldrich; 1804) to detect
3FLAG-P53. Images were captured and quantitation performed using the LI-
COR Odyssey imaging system.
Virus Reconstitution and Stocks. Here 1 μg of each recombinant MHV-68 BAC
DNA (Maxiprep DNA; Macherey-Nagel) was used to transfect 106 BHK-21
cells in a 6 cm diameter dish with X-tremeGENE HP (GE Healthcare). About
4 d after transfection, when CPE was visible, cells and media were harvested
and frozen-thawed. Viruses were passaged through NIH 3T3-CRE cells to
remove loxP-flanked BAC sequences. Loss of green fluorescence in viral
plaques was indicative of removal of BAC DNA, which expresses the GFP.
MHV-68 (v-WT) and v-WT.yfp virions were reconstituted from BAC DNA.
v-kLANA and v-kLANA.yfp have been described previously (30). Virus stocks
were prepared by infecting BHK-21 cells at 0.002 PFU/cell for 3 to 5 d. Me-
dium from infected cultures was harvested and cleared by centrifugation at
500 × g for 5 min at 4 °C. Viruses were recovered from cleared supernatants
by centrifugation at 15,000 × g for 2 h at 4 °C.
Mice. Female C57BL/6J mice were purchased from Charles River Laboratories
and housed and subjected to experimental procedures in specific pathogen-
free conditions at Instituto de Medicina Molecular (IMM). All experiments
were approved by the Direção-Geral de Alimentação e Veterinária (protocol
AEC_2010_017_PS_Rdt_General) and the IMM Animal Ethics Committee.
Infectivity Assays. Virus titration was performed in BHK-21 cells by suspension
assay (plaque assay). After a 4-d incubation at 37 °C, cells were fixed with 4%
formaldehyde in PBS and stained with 0.05% toluidine blue. Viral plaques
were counted manually under a plate microscope. Female C57 BL6 J mice
(age 6 to 8 wk) were infected intranasally with 104 PFU in 20 μL of PBS under
isofluorane anesthesia. Single-cell suspensions of spleens were prepared as
described previously (34). For the infectious center assay (ex vivo reactivation
assay), serially diluted splenocyte suspensions from individual mice were
cocultured with 5 × 105 BHK-21 cells in 6-cm dishes for 5 d at 37 °C. Cells were
fixed and stained and viral plaques were counted manually, as for the pla-
que assay. Preformed infectious virus titers in freeze-thawed splenocyte
suspensions were determined by a plaque assay. The frequency of viral
genome-positive cells was determined by limiting dilution combined with
PCR detection of viral genomes (35, 36). Pools from individual splenocyte
suspensions (starting at 2 × 106 cells) or FACS-sorted germinal center B cells
(CD19+CD95+GL7+) (30) were twofold serially diluted. Eight replicates for
each dilution were incubated with lysis buffer (10 mM Tris·HCl pH 8.3, 3 mM
MgCl2, 50 mM KCl, 0.45% Nonidet P-40, 0.45% Tween 20, and 0.5 mg/mL of
proteinase K), overnight at 37 °C and, after Proteinase K inactivation (95 °C
for 5 min), subjected to real-time qPCR. MHV-68 M9 gene-specific primers
and TaqMan probe and PCR settings have been described previously (35).
Positive and negative reactions were scored using Rotor Gene 6000 soft-
ware. The frequency of viral DNA+ cells was determined by regression
analysis of the number of cells vs. the fraction of PCR-negative results.
Results
LANA Residues 332 to 465 Mediate Latent KSHV Infection. We previ-
ously identified internal LANA sequence as critical for LANA-
mediated episome persistence. While N- and C-terminal LANA
are essential for episome persistence, deletion of internal LANA
regions induce a broad range of deficiencies, ranging from mild to
severe. These deficiencies were characterized using an episome
A B
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Fig. 2. BAC LANA-R Δ332–929 is abolished, and BAC LANA-R Δ262–320 is impaired for latently infected cell outgrowth. (A) BACΔLANA, BAC LANA-R, and
BAC containing LANA mutants were transfected into 293T cells. The cells were harvested after 48 h, and LANA expression was assessed by Western blot
analysis using a polyclonal Ab that recognizes the LANA internal repeat elements. (B) BACΔLANA, BAC LANA-R, and LANA mutants were each transfected
into 293T cells and harvested after 24 h. DNA was extracted by Hirt extraction (33). RNA was extracted with TRIzol and reverse-transcribed. The level of LANA
cDNA compared with KSHV DNA, as determined by real-time qPCR, was used to determine expression levels. (C and D) BAC LANA-R and mutants were
transfected in 293T cells. At 48 h posttransfection, the number of GFP-expressing cells (i.e., GFP expressed from the recombinant BAC) was assessed by flow
cytometry, and a cell suspension containing 1,000 green cells was plated and placed under selection, for which resistance is encoded by the BAC, in 150-mm
dishes. After 2.5 wk of selection, colonies were stained with crystal violet and counted. A representative experiment is shown in C, and average colony
outgrowths are shown in D. All data are from at least three independent experiments. ns, P > 0.05. **P < 0.01, independent-samples t test.




































maintenance assay in which LANA mediates episome persistence
of TR DNA. This assay has a broad dynamic range, allowing for
detection of LANA deficiencies ranging up to several thousand-
fold (13, 14, 37–39).
Since previous assays were performed in the absence of other
KSHV genes, we wished to assess the role of mild or modest
LANA deficiencies for virus persistence. It is possible that
comparatively “mild” deficiencies in LANA function could exert
a substantial effect on the ability of KSHV to persist; for in-
stance, compensatory recombination events that are selected for
in TR episomes in the absence of other virus genes would likely
induce lethal events for virus. Disruption of virus persistence due
to deletion of specific LANA sequences would indicate a critical
biological function.
We generated recombinant KSHV BAC16 (24) containing WT
LANA (BAC LANA-R), KSHV lacking LANA (BACΔLANA),
and KSHV containing LANAΔ288–320 (BAC LANA-RΔ288–320),
LANAΔ262–320 (BACLANA-RΔ262–320), LANAΔ465–929 (BAC
LANA-RΔ465–929), or LANAΔ332–929 (BACLANA-RΔ332–929)
(Fig. 1). LANAΔ288–320, LANAΔ262–320, LANAΔ465–929,
and LANAΔ332–929 have mild or modest episome maintenance
deficiencies of 3.0-, 14.4-, 3.8-, and 10.9-fold, respectively, which
contrast sharply with deficiencies of at least several hundred-
fold after deletion of distinct LANA sequences (13, 38).
LANAΔ262–320 is deficient since it lacks interaction with the
DNA replication factor C (RFC), engendering a deficiency for
LANA-mediated DNA replication, while LANAΔ288–320 retains
RFC interaction (14, 40).
Since LANA can regulate its own expression (41), LANA
expression was assessed from the recombinant LANA mutant
BACs. Following BAC transfection into 293T cells, LANA,
LANAΔ288–320, LANAΔ465–929, and LANAΔ262–320 could
each be detected by immunoblot migration at the appropriate
size (Fig. 2A). As expected, LANAΔ332–929, which lacks the
internal repeats to which most anti- LANA Abs are directed, was
not detected by immunoblot. Direct comparison of LANA ex-
pression through assessment of LANA transcript levels demon-
strated each of the LANA mutants was expressed at a level at
least as high as that of WT (Fig. 2B).
We assessed the recombinant KSHVs for the ability to estab-
lish latency and persist in cells. BACΔLANA, BACLANA-R, or BAC
containing LANAΔ288–320, LANAΔ262–320, LANAΔ465–929, or
LANAΔ332–929 was transfected into 293T cells. At 48 h post-
transfection, 1,000 virus-infected cells, as assessed by GFP ex-
pression from the recombinant viral genome, were seeded into
15-cm dishes and placed under hygromycin selection, for which
the recombinant genome encodes resistance. After 2.5 wk of
selection, the number of hygromycin-resistant 293T cell colonies
was determined (Fig. 2 C and D). As expected, BAC LANA-R
resulted in efficient outgrowth, while BACΔLANA, which lacks
LANA and thus cannot establish persistent latent infection, was
abolished for outgrowth. BAC LANA-R Δ288–320 persisted
similarly to BAC LANA-R, while BAC LANA-R Δ262–320
persisted at only 33% of the WT BAC LANA-R levels. BAC
LANA-R Δ465–929, which lacks most of the LANA internal
repeat elements, was reduced only modestly and persisted at
∼70% of WT levels. In stark contrast, BAC LANA-R Δ332–929,
which lacks all LANA internal repeat elements, lost the ability
to persist.
Since the only difference between LANAΔ465–929 and
LANAΔ332–929 is deletion of residues 332 to 465, we directly
tested the role of these LANA residues by deleting them in BAC
LANA-R Δ331–495. Following transfection of BAC LANA-R
Δ331–495 into 293T cells, LANA Δ331–495 was detected by
immunoblot migration at the appropriate size (Fig. 3A). Com-
pared with BAC LANA-R, BAC LANAΔ331–495 had highly
deficient outgrowth, at 25% of the level in WT BAC LANA-R
(Fig. 3 B and C). Taken together, these data indicate that LANA
residues 332 to 465 are necessary for the efficient establishment
of KSHV latency and persistence in cells.
LANA 332–465 Contains an Acidic Domain Reader Sequence That
Selectively Interacts with Nonacetylated p53. Within LANA resi-
dues 332 to 465, we identified amino acids 330 to 421 as having
high homology with the SET oncoprotein acidic domain reader
region (Fig. 4A). The SET reader region preferentially interacts
with unacetylated forms of lysine-rich ligands, including the
carboxy terminal domain of p53 (23). Alignment of the SET
acidic region with LANA reveals two overlapping regions of
homology between LANA amino acids 330 and 421, which en-
compasses almost all of the LANA 332 to 465 sequence neces-
sary for efficient virus persistence (Fig. 4A). A lower homology
match is also present in C-terminal LANA residues 845 to 895.
Since LANA interacts with p53 (42–44), we assessed the in-
teraction between the LANA acidic domain region and p53.
GFP LANA 275–435, which contains the acidic sequence,
coimmunoprecipitated with p53 with similar efficiency as that of
GFP LANA (Fig. 4B), indicating that this LANA region inter-
acts with p53. Since CBP acetylates p53, we evaluated the in-
teraction of LANA in the presence or absence of CBP
overexpression. As expected, LANA coimmunoprecipitated with
p53 (Fig. 4C, lane 5); however, in the presence of CBP expres-
sion, LANA’s interaction with p53 was substantially diminished








































Fig. 3. BAC LANA-R Δ331–495 is severely impaired for latently infected cell outgrowth. (A) BAC LANA-R and BAC LANA-R Δ331–495 were transfected into
293T cells. The cells were harvested after 48 h, and LANA expression was assessed by Western blot analysis. (B and C) BAC LANA-R and BAC LANA-R Δ331–495
were each transfected into 293T cells. At 48 h after transfection, the cells were plated and placed under selection as described in Fig. 2. Data in C are from at
least three independent experiments. *P < 0.05; **P < 0.01.












































interaction. Since CBP functionally interacts with LANA and
p53 (45, 46), we also examined LANA’s p53 binding in the ab-
sence of CBP overexpression.
We assessed LANA binding to an acetylation mimicking car-
boxy terminal domain p53 mutant, p53KQ, or to an acetylation-
deficient mutant, p53KR (23). After expression in 293T cells,
LANA coprecipitated with p53KR more efficiently than with WT
p53 (Fig. 5A). In direct contrast, LANA’s interaction with acet-
ylation mimicking p53KQ was substantially reduced (Fig. 5A).
Furthermore, GFP LANA 275–435 demonstrated a similar
pattern of interaction with enhanced binding to p53KR and re-
duced binding to p53KQ (Fig. 5B). Taken together, these results
indicate that the LANA acidic domain preferentially interacts
with unacetylated p53.
The LANA Acidic Domain Reader Is Required for Latency of Chimeric
MHV-68 in Vivo. We next interrogated the function of the acidic
domain reader of LANA in a more physiological setting. We and
others have previously described a v-kLANA chimeric virus in
which MHV-68 LANA is replaced by KSHV LANA in MHV-68
as a model system for investigating LANA function during
in vivo infection of mice (30, 47). KSHV LANA rescued the
ability of the chimeric virus to establish latent infection in vivo,
although at a moderately reduced level compared with wild-type
MHV-68. As expected, mutations in the essential LANA histone-
binding region or DNA-binding domain abolished the latency of
the chimeric virus (30). To assess the contribution of the internal
repeat regions of LANA to v-kLANA latency, we generated
recombinant chimeric viruses containing LANA Δ332–929 and
Δ465–929. Transcripts of LANA Δ465–929 and Δ332–929 were
detected following infection of BHK-21 cells with each mutant
virus (Fig. 6A). Both mutant viruses underwent lytic replication
normally in vitro (Fig. 6B).
A
B C
Fig. 4. The LANA SET homology sequence interacts with p53 and acetylation reduces LANA–p53 interaction. (A) Schematic of LANA with acidic SET ho-
mology regions indicated below. Sequence alignments were determined with LALIGN. Identity and similarity are shown. (B) GFP LANA 275–435 interacts with
p53. GFP, GFP-LANA, or GFP-LANA 275–435 and Flag-p53 were cotransfected into 293T cells. At 48 h after transfection, Flag p53 was immunoprecipitated with
M2-Flag Ab, and Western blot analysis was performed. (C) Expression of CBP, which acetylates p53, reduces the LANA–p53 interaction. pT7LANA, Flag-p53,
and HA-CBP were transfected into 293T cells. At 48 h after transfection, Flag p53 was immunoprecipitated using M2-Flag Ab, and Western blot analysis was
performed. Data in B and C are representative of at least three independent experiments.
Fig. 5. Decreased LANA interaction with acetylation mimicking p53KQ and increased LANA interaction with acetylation-deficient p53KR. GFP LANA (Left) and
GFP LANA 275–435 (Right) were coexpressed with Flag p53, p53KQ, or p53KR (p53 K acetylation sites 370, 372 to 373, 381 to 382, and 386 mutated to Q or R,
respectively) in 293T cells. At 48 h posttransfection, Flag p53 was immunoprecipitated, and Western blot analysis was performed. Results are representative of
at least three experiments. Quantitation of GFP LANA or GFP LANA 275–435 bands are shown. *Heavy chain, which comigrates with p53. V, Flag vector.




































We next inoculated mice intranasally and assessed viral la-
tency in the spleen at day 14 postinoculation, at the peak of
expansion of latently infected cells at this dose and route of in-
fection. Latent virus load was assessed by an ex vivo reactivation/
infectious assay that measures reactivating virus from total
splenocytes on coculture with permissive fibroblasts, and by
limiting dilution analysis with PCR detection of viral DNA-
positive cells to determine the frequency of infection.
v-Δ332–929 was undetectable in both assays (Fig. 6 C and D and
SI Appendix, Table S1). In contrast, v-Δ465–929 latency was in-
distinguishable from that of v-kLANA (Fig. 6 C and D and SI
Appendix, Table S1).
We next constructed a chimeric MHV-68 containing LANA
Δ331–495. The LANA Δ331–495 protein was expressed in in-
fected cells in vitro, migrating at appropriate size and with sim-
ilar levels as wild-type protein (Fig. 7A). v-Δ331–495 had similar
growth in vitro as v-kLANA and v-WT viruses (Fig. 7B). On
inoculation of mice, at 14 d after infection, v-Δ331–495 was
deficient for latency establishment compared with v-kLANA,
with undetectable virus in most mice and low levels in the
remaining mice in ex vivo reactivation/infectious titers (Fig. 7 C
and D, Left). In agreement with these results, the frequency of
infection in total splenocytes was roughly 10-fold lower for
v-Δ331–495 compared with v-kLANA (Fig. 7D, Right and SI
Appendix, Table S2). Therefore, LANA residues 332 to 465 of
the internal repeat region that contains the acidic domain reader
are critical not only for efficient KSHV latency establishment,
but also for chimeric virus latency in vivo.
Discussion
This work shows that LANA residues 330 to 421 contain an SET
homologous acidic domain reader sequence that preferentially
interacts with the unacetylated form of p53. Such a “reader”
sequence is functionally opposite of bromodomains, which bind
acetylated ligands (48). This LANA sequence may exert its ef-
fects on viral persistence through p53. LANA inhibits p53 ac-
tivity (42), and interaction with the unacetylated form of p53
could contribute to this inhibition. However, it is likely that
LANA also preferentially interacts with unacetylated forms of
additional proteins. The species-specific prediction of lysine
acetylation (SSPKA) program (49) identifies 49 host proteins
other than p53 that contain lysine clusters with the potential to
selectively bind acidic domain readers in an unacetylated form
(23). Many of these proteins have been described as potential
LANA-interacting partners (46, 50–55), and LANA may exert its
effects on virus persistence through one or more of these. For
instance, LANA interacts with the cAMP response element-
binding protein (CBP) and inhibits its acetylase and transcrip-
tional activity (46). Two LANA regions, C-terminal LANA and
the acidic domain reader sequence, interact with the CBP C/H3
region, and this region contains lysine residues that are predicted
to be acetylated (23).
LANA contains two tandem, partially overlapping acidic do-
main reader sequences between residues 330 and 421 and a
third, lower-homology C-terminal acidic domain reader se-
quence at amino acids 845 to 895 (Fig. 4). In contrast, 49 host
proteins identified as containing potential acidic domain reader
sequences generally contain less extensive acidic sequences of
approximately one-half the length of LANA 330 to 421 (23). The
basis for LANA’s extended acidic domain reader sequence is
unclear. Perhaps LANA acts as a multivalent receptor for one or
more unacetylated partners. Such interactions could be inhibi-
tory, similar to that of SET on p53, or could assemble active
complexes important for virus persistence.
LANA inhibits cis major histocompatibility complex (MHC)





Fig. 6. Deletion of kLANA residues 332 to 929 abolishes kLANA-MHV-68 latency in vivo. (A) Relative levels of kLANA transcripts from BHK-21 cells infected with 5
PFU/cell for 8 h. Expression of MHV68 M3, a lytic viral product, was also assessed as a measure of the level of infection. Bars indicate mean fold changes ± SD. (B)
Growth curves. BHK-21 cells were infected with 0.01 PFU/cell for 1 h and, after removal of inoculum and washing, incubated at 37 °C. Total virus titers at the
indicated times were determined by plaque assay. Time 0 represents the viral titer after washing inoculum. (C and D) Latent infection in the spleen at day 14 after
intranasal infection with 104 PFU. (C) Infectious center titers following reactivation from latency (closed circles) and preformed virus (open circles). Circles represent
individual mice. The horizontal bar indicates the mean, and the dashed line indicates the limit of detection. (D) Frequency of viral DNA-positive cells (bars) ± 95%
CIs in total splenocytes (Left) and FACS-sorted germinal center B cells (CD19+CD95+GL7+) (Right). Data are from pools of three to five spleens per infection group.
ND, not detectable. i denotes independent clone. NS, not significant; **P < 0.01; ***P < 0.001, Mann–Whitney U test.












































responsible for this function (56–58). The glutamine-rich repeat
sequence retards LANA synthesis, which is expected to reduce
defective ribosomal product processing, and also enhances the
stability of LANA. EBNA1, LANA’s functional episome mainte-
nance homolog in the Epstein–Barr virus, exhibits similar prop-
erties, which result in inhibition of antigen presentation by MHC
class I molecules (59, 60). However, despite these functions, de-
letion of the glutamine-rich region did not reduce LANA’s ability
to inhibit cis MHC class I peptide presentation (57) or virus
persistence in the experiments presented here. The LANA acidic
domain does not affect LANA synthesis or stability, but it does
inhibit cisMHC class I peptide presentation (57). The mechanism
for this inhibition is unknown, and it is intriguing to consider that
LANA may exert this effect through acidic domain interaction
with an unacetylated partner. Although the loss of such inhibition
in the absence of the acidic domain could contribute to a loss of
virus persistence in vivo, it would not account for the observed loss
of KSHV persistence in cell culture, suggesting that additional
factors are responsible.
In contrast to KSHV LANA, MHV68 LANA lacks repeat
elements, including an acidic domain reader sequence. Since the
MHV68 LANA DNA-binding domain multimerizes into higher-
order structures and recognizes DNA differently from KSHV
LANA (61), it is possible that the acidic domain reader sequence
has evolved in concert with differences in LANA’s recognition of
DNA. For instance, if the bend in DNA induced by KSHV
LANA signals a DNA damage response, similar to that triggered
by bends due to insertion/deletion loops (62, 63), such a response
could be countered by a recruited factor. In contrast, MHV68
LANA does not induce a bend in DNA and would not require
such an interaction.
In summary, here we have shown that LANA contains an
acidic domain reader, homologous to the SET acidic domain,
that recognizes the unacetylated form of tumor suppressor p53.
Like SET, the LANA acidic domain may function as a tran-
scriptional corepressor of p53. However, LANA’s acidic domain
reader could potentially interact with other cellular partners that
have a lysine cluster to exert its functional effects. Disrupting the
key interaction(s) through which the LANA acidic domain exerts
its effects may offer the opportunity for the development of
strategies to prevent or treat persistent KSHV infection and
associated tumors.
Data Availability. All study data are included in the main text and
SI Appendix.
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